Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ: ADMA )

21.73 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,575
Open 21.73
Bid (Size) 21.56 (3)
Ask (Size) 22.15 (1)
Prev. Close 21.73
Today's Range 21.73 - 21.73
52wk Range 6.230 - 23.64
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing? 
Via Chartmill
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill

Performance

YTD
+20.92%
+20.92%
1 Month
+6.94%
+6.94%
3 Month
+31.94%
+31.94%
6 Month
+38.50%
+38.50%
1 Year
+232.26%
+232.26%

More News

Read More
ADMA Biologics Statement on Tariffs
From ADMA Biologics, Inc.
Via GlobeNewswire
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
Peering Into ADMA Biologics's Recent Short Interest
Via Benzinga
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive.
Via Chartmill
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
Via Stocktwits
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 3, 2025
Via Benzinga
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
Via Stocktwits
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
Via Benzinga
There May Still Be Time to Get in on These 3 Trending Biotechs
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
SpringWorks Therapeutics Stock Gets A RS Rating Lift
Via Investor's Business Daily
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.